Artificial Liver Support with CytoSorb and MARS in Liver Failure: A Retrospective Propensity Matched Analysis

• Published in: Journal of clinical medicine Vol. 12; no. 6; p. 2258
• Main Authors: Popescu, Mihai, David, Corina, Marcu, Alexandra, Olita, Mihaela Roxana, Mihaila, Mariana, Tomescu, Dana
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: acute liver failure; acute-on-chronic liver failure; Apheresis; artificial liver support; Blood; Care and treatment; Clinical medicine; Comparative analysis; CytoSorb; Data collection; Dialysate; Failure; Infections; Laboratories; Liver diseases; Liver failure; liver support therapy; Methods; molecular adsorbent recirculating system; Mortality; Patients; Renal replacement therapy; Separators (Machines); Testing; Transplants & implants; Ventilators; Romania; Sweden; liver support therapy; artificial liver support; molecular adsorbent recirculating system; CytoSorb; acute liver failure; acute-on-chronic liver failure
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12062258

Liver failure represents a life-threatening organ dysfunction with liver transplantation as the only proven curable therapy to date. Liver assist devices have been extensively researched to either bridge such patients to transplantation or promote spontaneous recovery. The aim of our study was to compare two such devices, the Molecular Adsorbent Recirculating System (MARS) and CytoSorb, in patients with liver failure. We retrospectively included 15 patients who underwent MARS during their intensive care unit stay and matched them to 15 patients who underwent hemoadsorption using CytoSorb. Clinical and paraclinical data obtained after each individual session, after the course of treatment, as well as at the end of the intensive care unit stay were compared between the two groups. Single sessions of CytoSorb and MARS were both associated with a significant decrease in bilirubin ( = 0.04 and = 0.04, respectively) and ammonia levels ( = 0.04 and = 0.04, respectively), but only CytoSorb therapy was associated with a decrease in lactate dehydrogenase levels ( = 0.04) and in platelet count ( = 0.04). After the course of treatment, only CytoSorb was associated with a significant decrease in lactate ( = 0.01), bilirubin ( = 0.01), ammonia ( = 0.02), and lactate dehydrogenase levels ( = 0.01), while patients treated with MARS did not show any improvement in paraclinical liver tests. In addition, only CytoSorb treatment was associated with a significant improvement in the Model for End-Stage Liver Disease Score ( = 0.04). In conclusion, our results show a potential benefit of CytoSorb in rebalancing liver functional tests in patients with liver failure compared to MARS but the exact effects on patient outcome, including hospital length of stay and survival, should be further investigated in randomized control trials.